Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Farlong Pharmaceutical Completes Three-Year Clinical Trial to Determine Effects of Farlong NotoGinseng™

Just in time for American Heart Health Month, Farlong releases study demonstrating extract's supplementation has a positive influence on reducing the risk of cardiovascular disease


News provided by

Farlong Pharmaceutical

Feb 05, 2020, 06:00 ET

Share this article

Share toX

Share this article

Share toX

NotoGinseng Root
NotoGinseng Root

WALNUT, Calif., Feb. 5, 2020 /PRNewswire-PRWeb/ -- Just in time for American Heart Health Month, Farlong Pharmaceutical, a vertically integrated, plant-based ingredient and supplement company, announces the clinical trial results from a randomized, placebo-controlled, double-blind, parallel study on one hundred healthy adults to determine the effect of Farlong NotoGinseng™ (Farlong Ginseng Plus® Panax Notoginseng extract) on cholesterol and blood pressure, conducted December 2016 through June 2019.

The findings of this study demonstrate that Farlong NotoGinseng™ (Farlong Ginseng Plus® Panax Notoginseng extract) supplementation is well tolerated and has a positive influence on reducing the risk of cardiovascular disease by decreasing blood pressure and selectively increasing HDL-C.

Sponsored by Farlong Pharmaceutical and conducted by KGK Science, Inc., the primary objective was the difference in serum LDL-C from baseline to week 12 between Farlong NotoGinseng™ and placebo after 12 weeks of supplementation. The secondary objectives were the difference in serum LDL-C, blood pressure, triglycerides, HDL-C, total cholesterol and in endothelial vasodilation as measured by the EndoPAT from baseline to week eight and week 12 between Farlong NotoGinseng™ and placebo.

Over a 12-week period, the participants were given one serving (two capsules) of the investigational product or placebo to take orally at the same time every day, 30 minutes before a meal for 84 days.

The results showed a significant decrease in serum LDL-C in Farlong NotoGinseng™ group from baseline to week eight. LDL Cholesterol is sometimes called the "bad" cholesterol because a high LDL level leads to a buildup of cholesterol in people's arteries. There was a slight increase in serum HDL-C following 12 weeks of supplementation with Farlong NotoGinseng™. HDL (high-density lipoproteins) cholesterol is the "good" cholesterol. There were also within-group decreases in both systolic and diastolic blood pressures.

The placebo group had increases in systolic and diastolic blood pressures and a decrease in serum HDL-C. Clinicians suggest that if left unaddressed, these participants may progress to a disease state, and even a small reduction in blood pressure is clinically meaningful in populations at risk for developing cardiovascular diseases.

To review the full clinical study and results, please contact [email protected] or (888) 327-5664.

Farlong NotoGinseng™ is designed to help maintain normal health of the cardiovascular system. The capsule consists of highly concentrated pharmaceutical grade Ginseng Plus® Panax Notoginseng extract, containing high potency notoginsenoside R1, ginsenoside Rb1, ginsenoside Rg1, which are the most active components along with other minor ginsenosides, such as ginsenoside Rd, Re, Rb2 and Rg3, ext. to nutritionally support healthy heart function, blood circulation, and performance.

For more than 20 years, Farlong has created products using natural and herbal ingredients to promote a healthy and natural life, focusing on top quality ingredients and ancient Chinese roots. Farlong produces Panax Notoginseng from seed to shelf, beginning at their 6,000-acre GAP farm located in Yunnan Province, where 75% of world's medicinal botanicals originate from. The geographical area of the farm's location is known for harvesting specific medicinal Chinese herbs, proven to benefit the health and improvement for a variety of health conditions. Farlong combines traditional processing methods with the most advanced techniques, ensuring that all decoction ingredients are transferred to full-spectrum concentrated ingredients while achieving greater levels of stability and effectiveness.

About Farlong Pharmaceutical:
Since 1998, Farlong Pharmaceutical has combined ancient Oriental medicine and modern technology to create a line of natural and safe products that promote a healthy life. Farlong is a vertically integrated herbal ingredient and supplement company with its own GAP (Good Agricultural Practice) certified cultivation base, cGMP (Current Good Manufacturing Practice), certified manufacturing facilities and distribution channels for its unique and effective ingredients and formulas, including InnerPure® for colon detoxing, Lifeflower® breviscapine for cognitive health, Ginseng Plus® Panax Notoginseng™ extract for heart health and AstaBest™ Astaxanthin for antioxidant nutrition. For more information, visit Farlong.com for supplements and 300+ ingredients, and follow on Facebook, Twitter and Instagram.

SOURCE Farlong Pharmaceutical

Modal title

NotoGinseng Ultrafine Powder
NotoGinseng Ultrafine Powder
Heart Advanced Support
Heart Advanced Support
NotoGinseng Ultrafine Powder Heart Advanced Support

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.